Stay updated with breaking news from Normane Sharpless. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
G1 Therapeutics, Inc. (NASDAQ:GTHX – Get Rating) was the target of a large decrease in short interest in May. As of May 31st, there was short interest totalling 2,960,000 shares, a decrease of 5.1% from the May 15th total of 3,120,000 shares. Based on an average trading volume of 886,800 shares, the days-to-cover ratio is […]
G1 Therapeutics, Inc. (NASDAQ:GTHX – Get Rating) has been given an average rating of “Moderate Buy” by the six analysts that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 1 year target […]
G1 Therapeutics (NASDAQ:GTHX – Get Rating) and GlobeStar Therapeutics (OTCMKTS:GSTC – Get Rating) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, risk and profitability. Institutional & Insider Ownership 53.1% of G1 Therapeutics shares […]
G1 Therapeutics, Inc. (NASDAQ:GTHX – Get Rating) was the recipient of a significant decrease in short interest during the month of April. As of April 30th, there was short interest totalling 3,310,000 shares, a decrease of 12.4% from the April 15th total of 3,780,000 shares. Based on an average daily trading volume, of 1,190,000 shares, […]
Shares of G1 Therapeutics, Inc. (NASDAQ:GTHX – Get Rating) have received an average recommendation of “Moderate Buy” from the six research firms that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12 month […]